APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihyperuricemic Agents

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antihyperuricemic Agents Market Analysis and Forecast 2026-2032

30 December 2025215 pages

Choose your research edition.

Industry ResearchAntihyperuricemic Agents Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihyperuricemic Agents Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Antihyperuricemic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihyperuricemic Agents Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihyperuricemic Agents Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antihyperuricemic Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antihyperuricemic Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antihyperuricemic Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antihyperuricemic Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antihyperuricemic Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antihyperuricemic Agents include Accord Healthcare, ALP Pharm, APOTEX, Casper Pharma, Dr. Reddys Laboratories, Gentec Pharmaceutical Group, Hikma, Indoco Remedies and Ipca Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antihyperuricemic Agents, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antihyperuricemic Agents, also provides the sales of main regions and countries. Of the upcoming market potential for Antihyperuricemic Agents, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antihyperuricemic Agents sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antihyperuricemic Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antihyperuricemic Agents sales, projected growth trends, production technology, application and end-user industry.

Antihyperuricemic Agents Segment by Company

Accord Healthcare

ALP Pharm

APOTEX

Casper Pharma

Dr. Reddys Laboratories

Gentec Pharmaceutical Group

Hikma

Indoco Remedies

Ipca Laboratories

Lupin

Medinova

NorthStar Healthcare

Odan Laboratories

Rhea Pharmaceutical

TEIJIN

Waterstone Pharmaceuticals

West Ward Pharmaceuticals

Wockhardt

Zydus Pharmaceuticals

Beijing Jialin Pharmaceutical

Hangzhou Zhuyangxin Pharmaceutical

Jiangsu Hengrui Medicine

Jiangsu Wanbang Biopharmaceuticals

KPC Pharmaceuticals

Mylan

Sun Pharmaceutical

Teva

Tonghua Limin

Takeda Pharmaceuticals

YiChang HEC ChangJiang Pharmaceutical

Antihyperuricemic Agents Segment by Type

Inhibit Uric Acid Production Agents

Promote Uric Acid Excretion Agents

Others

Antihyperuricemic Agents Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Antihyperuricemic Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihyperuricemic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihyperuricemic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihyperuricemic Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antihyperuricemic Agents in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antihyperuricemic Agents manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antihyperuricemic Agents sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antihyperuricemic Agents Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Inhibit Uric Acid Production Agents Major Manufacturers Table 3. Promote Uric Acid Excretion Agents Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Antihyperuricemic Agents Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Retail Pharmacies Major Manufacturers Table 7. Online Pharmacies Major Manufacturers Table 8. Hospital Pharmacies Major Manufacturers Table 9. Antihyperuricemic Agents Industry Trends Table 10. Antihyperuricemic Agents Industry Drivers Table 11. Antihyperuricemic Agents Industry Opportunities and Challenges Table 12. Antihyperuricemic Agents Industry Restraints Table 13. Global Antihyperuricemic Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Antihyperuricemic Agents Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Antihyperuricemic Agents Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Antihyperuricemic Agents Revenue Market Share by Region (2021-2026) Table 17. Global Antihyperuricemic Agents Revenue Market Share by Region (2027-2032) Table 18. Global Antihyperuricemic Agents Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Antihyperuricemic Agents Sales by Region (2021-2026) & (K Units) Table 20. Global Antihyperuricemic Agents Sales by Region (2027-2032) & (K Units) Table 21. Global Antihyperuricemic Agents Sales Market Share by Region (2021-2026) Table 22. Global Antihyperuricemic Agents Sales Market Share by Region (2027-2032) Table 23. Global Antihyperuricemic Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Antihyperuricemic Agents Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Antihyperuricemic Agents Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Antihyperuricemic Agents Sales Market Share by Manufacturers (2021-2026) Table 27. Global Antihyperuricemic Agents Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Antihyperuricemic Agents Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Antihyperuricemic Agents Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Antihyperuricemic Agents Manufacturers, Product Type & Application Table 31. Global Antihyperuricemic Agents Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Antihyperuricemic Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Antihyperuricemic Agents Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Antihyperuricemic Agents Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Antihyperuricemic Agents Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Antihyperuricemic Agents Revenue Market Share by Type (2021-2026) Table 38. Global Antihyperuricemic Agents Revenue Market Share by Type (2027-2032) Table 39. Global Antihyperuricemic Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 41. Global Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 42. Global Antihyperuricemic Agents Sales Market Share by Type (2021-2026) Table 43. Global Antihyperuricemic Agents Sales Market Share by Type (2027-2032) Table 44. Global Antihyperuricemic Agents Price by Type (2021-2026) & (US$/Unit) Table 45. Global Antihyperuricemic Agents Price by Type (2027-2032) & (US$/Unit) Table 46. Global Antihyperuricemic Agents Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Antihyperuricemic Agents Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Antihyperuricemic Agents Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Antihyperuricemic Agents Revenue Market Share by Application (2021-2026) Table 50. Global Antihyperuricemic Agents Revenue Market Share by Application (2027-2032) Table 51. Global Antihyperuricemic Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 53. Global Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 54. Global Antihyperuricemic Agents Sales Market Share by Application (2021-2026) Table 55. Global Antihyperuricemic Agents Sales Market Share by Application (2027-2032) Table 56. Global Antihyperuricemic Agents Price by Application (2021-2026) & (US$/Unit) Table 57. Global Antihyperuricemic Agents Price by Application (2027-2032) & (US$/Unit) Table 58. Accord Healthcare Company Information Table 59. Accord Healthcare Business Overview Table 60. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Accord Healthcare Antihyperuricemic Agents Product Portfolio Table 62. Accord Healthcare Recent Development Table 63. ALP Pharm Company Information Table 64. ALP Pharm Business Overview Table 65. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. ALP Pharm Antihyperuricemic Agents Product Portfolio Table 67. ALP Pharm Recent Development Table 68. APOTEX Company Information Table 69. APOTEX Business Overview Table 70. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. APOTEX Antihyperuricemic Agents Product Portfolio Table 72. APOTEX Recent Development Table 73. Casper Pharma Company Information Table 74. Casper Pharma Business Overview Table 75. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Casper Pharma Antihyperuricemic Agents Product Portfolio Table 77. Casper Pharma Recent Development Table 78. Dr. Reddys Laboratories Company Information Table 79. Dr. Reddys Laboratories Business Overview Table 80. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio Table 82. Dr. Reddys Laboratories Recent Development Table 83. Gentec Pharmaceutical Group Company Information Table 84. Gentec Pharmaceutical Group Business Overview Table 85. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio Table 87. Gentec Pharmaceutical Group Recent Development Table 88. Hikma Company Information Table 89. Hikma Business Overview Table 90. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hikma Antihyperuricemic Agents Product Portfolio Table 92. Hikma Recent Development Table 93. Indoco Remedies Company Information Table 94. Indoco Remedies Business Overview Table 95. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Indoco Remedies Antihyperuricemic Agents Product Portfolio Table 97. Indoco Remedies Recent Development Table 98. Ipca Laboratories Company Information Table 99. Ipca Laboratories Business Overview Table 100. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Ipca Laboratories Antihyperuricemic Agents Product Portfolio Table 102. Ipca Laboratories Recent Development Table 103. Lupin Company Information Table 104. Lupin Business Overview Table 105. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Lupin Antihyperuricemic Agents Product Portfolio Table 107. Lupin Recent Development Table 108. Medinova Company Information Table 109. Medinova Business Overview Table 110. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Medinova Antihyperuricemic Agents Product Portfolio Table 112. Medinova Recent Development Table 113. NorthStar Healthcare Company Information Table 114. NorthStar Healthcare Business Overview Table 115. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. NorthStar Healthcare Antihyperuricemic Agents Product Portfolio Table 117. NorthStar Healthcare Recent Development Table 118. Odan Laboratories Company Information Table 119. Odan Laboratories Business Overview Table 120. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Odan Laboratories Antihyperuricemic Agents Product Portfolio Table 122. Odan Laboratories Recent Development Table 123. Rhea Pharmaceutical Company Information Table 124. Rhea Pharmaceutical Business Overview Table 125. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 127. Rhea Pharmaceutical Recent Development Table 128. TEIJIN Company Information Table 129. TEIJIN Business Overview Table 130. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. TEIJIN Antihyperuricemic Agents Product Portfolio Table 132. TEIJIN Recent Development Table 133. Waterstone Pharmaceuticals Company Information Table 134. Waterstone Pharmaceuticals Business Overview Table 135. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 137. Waterstone Pharmaceuticals Recent Development Table 138. West Ward Pharmaceuticals Company Information Table 139. West Ward Pharmaceuticals Business Overview Table 140. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 142. West Ward Pharmaceuticals Recent Development Table 143. Wockhardt Company Information Table 144. Wockhardt Business Overview Table 145. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Wockhardt Antihyperuricemic Agents Product Portfolio Table 147. Wockhardt Recent Development Table 148. Zydus Pharmaceuticals Company Information Table 149. Zydus Pharmaceuticals Business Overview Table 150. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 152. Zydus Pharmaceuticals Recent Development Table 153. Beijing Jialin Pharmaceutical Company Information Table 154. Beijing Jialin Pharmaceutical Business Overview Table 155. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 157. Beijing Jialin Pharmaceutical Recent Development Table 158. Hangzhou Zhuyangxin Pharmaceutical Company Information Table 159. Hangzhou Zhuyangxin Pharmaceutical Business Overview Table 160. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 162. Hangzhou Zhuyangxin Pharmaceutical Recent Development Table 163. Jiangsu Hengrui Medicine Company Information Table 164. Jiangsu Hengrui Medicine Business Overview Table 165. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio Table 167. Jiangsu Hengrui Medicine Recent Development Table 168. Jiangsu Wanbang Biopharmaceuticals Company Information Table 169. Jiangsu Wanbang Biopharmaceuticals Business Overview Table 170. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio Table 172. Jiangsu Wanbang Biopharmaceuticals Recent Development Table 173. KPC Pharmaceuticals Company Information Table 174. KPC Pharmaceuticals Business Overview Table 175. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 177. KPC Pharmaceuticals Recent Development Table 178. Mylan Company Information Table 179. Mylan Business Overview Table 180. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Mylan Antihyperuricemic Agents Product Portfolio Table 182. Mylan Recent Development Table 183. Sun Pharmaceutical Company Information Table 184. Sun Pharmaceutical Business Overview Table 185. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 187. Sun Pharmaceutical Recent Development Table 188. Teva Company Information Table 189. Teva Business Overview Table 190. Teva Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Teva Antihyperuricemic Agents Product Portfolio Table 192. Teva Recent Development Table 193. Tonghua Limin Company Information Table 194. Tonghua Limin Business Overview Table 195. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 196. Tonghua Limin Antihyperuricemic Agents Product Portfolio Table 197. Tonghua Limin Recent Development Table 198. Takeda Pharmaceuticals Company Information Table 199. Takeda Pharmaceuticals Business Overview Table 200. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 201. Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 202. Takeda Pharmaceuticals Recent Development Table 203. YiChang HEC ChangJiang Pharmaceutical Company Information Table 204. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 205. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 206. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 207. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 208. North America Antihyperuricemic Agents Revenue by Type (2021-2026) & (US$ Million) Table 209. North America Antihyperuricemic Agents Revenue by Type (2027-2032) & (US$ Million) Table 210. North America Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 211. North America Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 212. North America Antihyperuricemic Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 213. North America Antihyperuricemic Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 214. North America Antihyperuricemic Agents Revenue by Application (2021-2026) & (US$ Million) Table 215. North America Antihyperuricemic Agents Revenue by Application (2027-2032) & (US$ Million) Table 216. North America Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 217. North America Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 218. North America Antihyperuricemic Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 219. North America Antihyperuricemic Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 220. North America Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 221. North America Antihyperuricemic Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 222. North America Antihyperuricemic Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 223. North America Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 224. North America Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 225. North America Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 226. North America Antihyperuricemic Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 227. North America Antihyperuricemic Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 228. United States Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 229. Canada Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 230. Europe Antihyperuricemic Agents Revenue by Type (2021-2026) & (US$ Million) Table 231. Europe Antihyperuricemic Agents Revenue by Type (2027-2032) & (US$ Million) Table 232. Europe Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 233. Europe Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 234. Europe Antihyperuricemic Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 235. Europe Antihyperuricemic Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 236. Europe Antihyperuricemic Agents Revenue by Application (2021-2026) & (US$ Million) Table 237. Europe Antihyperuricemic Agents Revenue by Application (2027-2032) & (US$ Million) Table 238. Europe Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 239. Europe Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 240. Europe Antihyperuricemic Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 241. Europe Antihyperuricemic Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 242. Europe Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 243. Europe Antihyperuricemic Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 244. Europe Antihyperuricemic Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 245. Europe Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 246. Europe Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 247. Europe Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 248. Europe Antihyperuricemic Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 249. Europe Antihyperuricemic Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 250. Germany Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 251. France Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 252. U.K. Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 253. Italy Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 254. Netherlands Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 255. China Antihyperuricemic Agents Revenue by Type (2021-2026) & (US$ Million) Table 256. China Antihyperuricemic Agents Revenue by Type (2027-2032) & (US$ Million) Table 257. China Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 258. China Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 259. China Antihyperuricemic Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 260. China Antihyperuricemic Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 261. China Antihyperuricemic Agents Revenue by Application (2021-2026) & (US$ Million) Table 262. China Antihyperuricemic Agents Revenue by Application (2027-2032) & (US$ Million) Table 263. China Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 264. China Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 265. China Antihyperuricemic Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 266. China Antihyperuricemic Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 267. Asia Antihyperuricemic Agents Revenue by Type (2021-2026) & (US$ Million) Table 268. Asia Antihyperuricemic Agents Revenue by Type (2027-2032) & (US$ Million) Table 269. Asia Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 270. Asia Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 271. Asia Antihyperuricemic Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 272. Asia Antihyperuricemic Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 273. Asia Antihyperuricemic Agents Revenue by Application (2021-2026) & (US$ Million) Table 274. Asia Antihyperuricemic Agents Revenue by Application (2027-2032) & (US$ Million) Table 275. Asia Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 276. Asia Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 277. Asia Antihyperuricemic Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 278. Asia Antihyperuricemic Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 279. Asia Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 280. Asia Antihyperuricemic Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 281. Asia Antihyperuricemic Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 282. Asia Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 283. Asia Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 284. Asia Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 285. Asia Antihyperuricemic Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 286. Asia Antihyperuricemic Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 287. Japan Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 288. South Korea Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 289. India Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 290. Australia Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 291. China Taiwan Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 292. Southeast Asia Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 293. SAMEA Antihyperuricemic Agents Revenue by Type (2021-2026) & (US$ Million) Table 294. SAMEA Antihyperuricemic Agents Revenue by Type (2027-2032) & (US$ Million) Table 295. SAMEA Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 296. SAMEA Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 297. SAMEA Antihyperuricemic Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 298. SAMEA Antihyperuricemic Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 299. SAMEA Antihyperuricemic Agents Revenue by Application (2021-2026) & (US$ Million) Table 300. SAMEA Antihyperuricemic Agents Revenue by Application (2027-2032) & (US$ Million) Table 301. SAMEA Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 302. SAMEA Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 303. SAMEA Antihyperuricemic Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 304. SAMEA Antihyperuricemic Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 305. SAMEA Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 306. SAMEA Antihyperuricemic Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 307. SAMEA Antihyperuricemic Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 308. SAMEA Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 309. SAMEA Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 310. SAMEA Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 311. SAMEA Antihyperuricemic Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 312. SAMEA Antihyperuricemic Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 313. Brazil Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 314. Argentina Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 315. Chile Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 316. Colombia Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 317. Peru Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 318. Saudi Arabia Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 319. Israel Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 320. UAE Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 321. Turkey Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 322. Iran Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 323. Egypt Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Table 324. Key Raw Materials Table 325. Raw Materials Key Suppliers Table 326. Antihyperuricemic Agents Distributors List Table 327. Antihyperuricemic Agents Customers List Table 328. Research Programs/Design for This Report Table 329. Authors List of This Report Table 330. Secondary Sources Table 331. Primary Sources List of Figures Figure 1. Antihyperuricemic Agents Image Figure 2. Global Antihyperuricemic Agents Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihyperuricemic Agents Market Size Share 2021 VS 2025 VS 2032 Figure 4. Inhibit Uric Acid Production Agents Image Figure 5. Promote Uric Acid Excretion Agents Image Figure 6. Others Image Figure 7. Global Antihyperuricemic Agents Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antihyperuricemic Agents Market Size Share 2021 VS 2025 VS 2032 Figure 9. Retail Pharmacies Image Figure 10. Online Pharmacies Image Figure 11. Hospital Pharmacies Image Figure 12. Global Antihyperuricemic Agents Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Figure 14. Global Antihyperuricemic Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Antihyperuricemic Agents Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Antihyperuricemic Agents Revenue Market Share by Region (2021-2032) Figure 17. Global Antihyperuricemic Agents Sales (2021-2032) & (K Units) Figure 18. Global Antihyperuricemic Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Antihyperuricemic Agents Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Antihyperuricemic Agents Sales YoY (2021-2032) & (K Units) Figure 21. Europe Antihyperuricemic Agents Sales YoY (2021-2032) & (K Units) Figure 22. China Antihyperuricemic Agents Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Antihyperuricemic Agents Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Antihyperuricemic Agents Sales YoY (2021-2032) & (K Units) Figure 25. Global Antihyperuricemic Agents Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Antihyperuricemic Agents Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Antihyperuricemic Agents Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Antihyperuricemic Agents Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Antihyperuricemic Agents Revenue Market Share by Type (2021-2032) Figure 31. Global Antihyperuricemic Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Antihyperuricemic Agents Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Antihyperuricemic Agents Sales Market Share by Type (2021-2032) Figure 34. Global Antihyperuricemic Agents Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Antihyperuricemic Agents Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Antihyperuricemic Agents Revenue Market Share by Application (2021-2032) Figure 37. Global Antihyperuricemic Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Antihyperuricemic Agents Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Antihyperuricemic Agents Sales Market Share by Application (2021-2032) Figure 40. North America Antihyperuricemic Agents Revenue Share by Type (2021-2032) Figure 41. North America Antihyperuricemic Agents Sales Share by Type (2021-2032) Figure 42. North America Antihyperuricemic Agents Revenue Share by Application (2021-2032) Figure 43. North America Antihyperuricemic Agents Sales Share by Application (2021-2032) Figure 44. North America Antihyperuricemic Agents Revenue Share by Country (2021-2032) Figure 45. North America Antihyperuricemic Agents Sales Share by Country (2021-2032) Figure 46. Europe Antihyperuricemic Agents Revenue Share by Type (2021-2032) Figure 47. Europe Antihyperuricemic Agents Sales Share by Type (2021-2032) Figure 48. Europe Antihyperuricemic Agents Revenue Share by Application (2021-2032) Figure 49. Europe Antihyperuricemic Agents Sales Share by Application (2021-2032) Figure 50. Europe Antihyperuricemic Agents Revenue Share by Country (2021-2032) Figure 51. Europe Antihyperuricemic Agents Sales Share by Country (2021-2032) Figure 52. China Antihyperuricemic Agents Revenue Share by Type (2021-2032) Figure 53. China Antihyperuricemic Agents Sales Share by Type (2021-2032) Figure 54. China Antihyperuricemic Agents Revenue Share by Application (2021-2032) Figure 55. China Antihyperuricemic Agents Sales Share by Application (2021-2032) Figure 56. Asia Antihyperuricemic Agents Revenue Share by Type (2021-2032) Figure 57. Asia Antihyperuricemic Agents Sales Share by Type (2021-2032

Scope & coverage.

Types
  • Inhibit Uric Acid Production Agents
  • Promote Uric Acid Excretion Agents
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Accord Healthcare
  • ALP Pharm
  • APOTEX
  • Casper Pharma
  • Dr. Reddys Laboratories
  • Gentec Pharmaceutical Group
  • Hikma
  • Indoco Remedies
  • Ipca Laboratories
  • Lupin
  • Medinova
  • NorthStar Healthcare
  • Odan Laboratories
  • Rhea Pharmaceutical
  • TEIJIN
  • Waterstone Pharmaceuticals
  • West Ward Pharmaceuticals
  • Wockhardt
  • Zydus Pharmaceuticals
  • Beijing Jialin Pharmaceutical
  • Hangzhou Zhuyangxin Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Jiangsu Wanbang Biopharmaceuticals
  • KPC Pharmaceuticals
  • Mylan
  • Sun Pharmaceutical
  • Teva
  • Tonghua Limin
  • Takeda Pharmaceuticals
  • YiChang HEC ChangJiang Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antihyperuricemic Agents Market by Type
  3. 1.2.1 Global Antihyperuricemic Agents Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Inhibit Uric Acid Production Agents
  5. 1.2.3 Promote Uric Acid Excretion Agents
  6. 1.2.4 Others
  7. 1.3 Antihyperuricemic Agents Market by Application
  8. 1.3.1 Global Antihyperuricemic Agents Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Retail Pharmacies
  10. 1.3.3 Online Pharmacies
  11. 1.3.4 Hospital Pharmacies
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Antihyperuricemic Agents Market Dynamics
  1. 2.1 Antihyperuricemic Agents Industry Trends
  2. 2.2 Antihyperuricemic Agents Industry Drivers
  3. 2.3 Antihyperuricemic Agents Industry Opportunities and Challenges
  4. 2.4 Antihyperuricemic Agents Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antihyperuricemic Agents Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antihyperuricemic Agents Revenue by Region
  3. 3.2.1 Global Antihyperuricemic Agents Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antihyperuricemic Agents Revenue by Region (2021-2026)
  5. 3.2.3 Global Antihyperuricemic Agents Revenue by Region (2027-2032)
  6. 3.2.4 Global Antihyperuricemic Agents Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antihyperuricemic Agents Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antihyperuricemic Agents Sales by Region
  9. 3.4.1 Global Antihyperuricemic Agents Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antihyperuricemic Agents Sales by Region (2021-2026)
  11. 3.4.3 Global Antihyperuricemic Agents Sales by Region (2027-2032)
  12. 3.4.4 Global Antihyperuricemic Agents Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antihyperuricemic Agents Revenue by Manufacturers
  2. 4.1.1 Global Antihyperuricemic Agents Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antihyperuricemic Agents Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antihyperuricemic Agents Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antihyperuricemic Agents Sales by Manufacturers
  6. 4.2.1 Global Antihyperuricemic Agents Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antihyperuricemic Agents Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antihyperuricemic Agents Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antihyperuricemic Agents Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antihyperuricemic Agents Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antihyperuricemic Agents Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antihyperuricemic Agents Manufacturers, Product Type & Application
  13. 4.7 Global Antihyperuricemic Agents Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antihyperuricemic Agents Market CR5 and HHI
  16. 4.8.2 2025 Antihyperuricemic Agents Tier 1, Tier 2, and Tier 3
5 Antihyperuricemic Agents Market by Type
  1. 5.1 Global Antihyperuricemic Agents Revenue by Type
  2. 5.1.1 Global Antihyperuricemic Agents Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antihyperuricemic Agents Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antihyperuricemic Agents Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antihyperuricemic Agents Sales by Type
  6. 5.2.1 Global Antihyperuricemic Agents Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antihyperuricemic Agents Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Antihyperuricemic Agents Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antihyperuricemic Agents Price by Type
6 Antihyperuricemic Agents Market by Application
  1. 6.1 Global Antihyperuricemic Agents Revenue by Application
  2. 6.1.1 Global Antihyperuricemic Agents Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antihyperuricemic Agents Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antihyperuricemic Agents Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antihyperuricemic Agents Sales by Application
  6. 6.2.1 Global Antihyperuricemic Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antihyperuricemic Agents Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Antihyperuricemic Agents Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antihyperuricemic Agents Price by Application
7 Company Profiles
  1. 7.1 Accord Healthcare
  2. 7.1.1 Accord Healthcare Company Information
  3. 7.1.2 Accord Healthcare Business Overview
  4. 7.1.3 Accord Healthcare Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Accord Healthcare Antihyperuricemic Agents Product Portfolio
  6. 7.1.5 Accord Healthcare Recent Developments
  7. 7.2 ALP Pharm
  8. 7.2.1 ALP Pharm Company Information
  9. 7.2.2 ALP Pharm Business Overview
  10. 7.2.3 ALP Pharm Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 ALP Pharm Antihyperuricemic Agents Product Portfolio
  12. 7.2.5 ALP Pharm Recent Developments
  13. 7.3 APOTEX
  14. 7.3.1 APOTEX Company Information
  15. 7.3.2 APOTEX Business Overview
  16. 7.3.3 APOTEX Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 APOTEX Antihyperuricemic Agents Product Portfolio
  18. 7.3.5 APOTEX Recent Developments
  19. 7.4 Casper Pharma
  20. 7.4.1 Casper Pharma Company Information
  21. 7.4.2 Casper Pharma Business Overview
  22. 7.4.3 Casper Pharma Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Casper Pharma Antihyperuricemic Agents Product Portfolio
  24. 7.4.5 Casper Pharma Recent Developments
  25. 7.5 Dr. Reddys Laboratories
  26. 7.5.1 Dr. Reddys Laboratories Company Information
  27. 7.5.2 Dr. Reddys Laboratories Business Overview
  28. 7.5.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio
  30. 7.5.5 Dr. Reddys Laboratories Recent Developments
  31. 7.6 Gentec Pharmaceutical Group
  32. 7.6.1 Gentec Pharmaceutical Group Company Information
  33. 7.6.2 Gentec Pharmaceutical Group Business Overview
  34. 7.6.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio
  36. 7.6.5 Gentec Pharmaceutical Group Recent Developments
  37. 7.7 Hikma
  38. 7.7.1 Hikma Company Information
  39. 7.7.2 Hikma Business Overview
  40. 7.7.3 Hikma Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Hikma Antihyperuricemic Agents Product Portfolio
  42. 7.7.5 Hikma Recent Developments
  43. 7.8 Indoco Remedies
  44. 7.8.1 Indoco Remedies Company Information
  45. 7.8.2 Indoco Remedies Business Overview
  46. 7.8.3 Indoco Remedies Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Indoco Remedies Antihyperuricemic Agents Product Portfolio
  48. 7.8.5 Indoco Remedies Recent Developments
  49. 7.9 Ipca Laboratories
  50. 7.9.1 Ipca Laboratories Company Information
  51. 7.9.2 Ipca Laboratories Business Overview
  52. 7.9.3 Ipca Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Ipca Laboratories Antihyperuricemic Agents Product Portfolio
  54. 7.9.5 Ipca Laboratories Recent Developments
  55. 7.10 Lupin
  56. 7.10.1 Lupin Company Information
  57. 7.10.2 Lupin Business Overview
  58. 7.10.3 Lupin Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Lupin Antihyperuricemic Agents Product Portfolio
  60. 7.10.5 Lupin Recent Developments
  61. 7.11 Medinova
  62. 7.11.1 Medinova Company Information
  63. 7.11.2 Medinova Business Overview
  64. 7.11.3 Medinova Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Medinova Antihyperuricemic Agents Product Portfolio
  66. 7.11.5 Medinova Recent Developments
  67. 7.12 NorthStar Healthcare
  68. 7.12.1 NorthStar Healthcare Company Information
  69. 7.12.2 NorthStar Healthcare Business Overview
  70. 7.12.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 NorthStar Healthcare Antihyperuricemic Agents Product Portfolio
  72. 7.12.5 NorthStar Healthcare Recent Developments
  73. 7.13 Odan Laboratories
  74. 7.13.1 Odan Laboratories Company Information
  75. 7.13.2 Odan Laboratories Business Overview
  76. 7.13.3 Odan Laboratories Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Odan Laboratories Antihyperuricemic Agents Product Portfolio
  78. 7.13.5 Odan Laboratories Recent Developments
  79. 7.14 Rhea Pharmaceutical
  80. 7.14.1 Rhea Pharmaceutical Company Information
  81. 7.14.2 Rhea Pharmaceutical Business Overview
  82. 7.14.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio
  84. 7.14.5 Rhea Pharmaceutical Recent Developments
  85. 7.15 TEIJIN
  86. 7.15.1 TEIJIN Company Information
  87. 7.15.2 TEIJIN Business Overview
  88. 7.15.3 TEIJIN Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 TEIJIN Antihyperuricemic Agents Product Portfolio
  90. 7.15.5 TEIJIN Recent Developments
  91. 7.16 Waterstone Pharmaceuticals
  92. 7.16.1 Waterstone Pharmaceuticals Company Information
  93. 7.16.2 Waterstone Pharmaceuticals Business Overview
  94. 7.16.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  96. 7.16.5 Waterstone Pharmaceuticals Recent Developments
  97. 7.17 West Ward Pharmaceuticals
  98. 7.17.1 West Ward Pharmaceuticals Company Information
  99. 7.17.2 West Ward Pharmaceuticals Business Overview
  100. 7.17.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  102. 7.17.5 West Ward Pharmaceuticals Recent Developments
  103. 7.18 Wockhardt
  104. 7.18.1 Wockhardt Company Information
  105. 7.18.2 Wockhardt Business Overview
  106. 7.18.3 Wockhardt Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Wockhardt Antihyperuricemic Agents Product Portfolio
  108. 7.18.5 Wockhardt Recent Developments
  109. 7.19 Zydus Pharmaceuticals
  110. 7.19.1 Zydus Pharmaceuticals Company Information
  111. 7.19.2 Zydus Pharmaceuticals Business Overview
  112. 7.19.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  114. 7.19.5 Zydus Pharmaceuticals Recent Developments
  115. 7.20 Beijing Jialin Pharmaceutical
  116. 7.20.1 Beijing Jialin Pharmaceutical Company Information
  117. 7.20.2 Beijing Jialin Pharmaceutical Business Overview
  118. 7.20.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio
  120. 7.20.5 Beijing Jialin Pharmaceutical Recent Developments
  121. 7.21 Hangzhou Zhuyangxin Pharmaceutical
  122. 7.21.1 Hangzhou Zhuyangxin Pharmaceutical Company Information
  123. 7.21.2 Hangzhou Zhuyangxin Pharmaceutical Business Overview
  124. 7.21.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio
  126. 7.21.5 Hangzhou Zhuyangxin Pharmaceutical Recent Developments
  127. 7.22 Jiangsu Hengrui Medicine
  128. 7.22.1 Jiangsu Hengrui Medicine Company Information
  129. 7.22.2 Jiangsu Hengrui Medicine Business Overview
  130. 7.22.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio
  132. 7.22.5 Jiangsu Hengrui Medicine Recent Developments
  133. 7.23 Jiangsu Wanbang Biopharmaceuticals
  134. 7.23.1 Jiangsu Wanbang Biopharmaceuticals Company Information
  135. 7.23.2 Jiangsu Wanbang Biopharmaceuticals Business Overview
  136. 7.23.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio
  138. 7.23.5 Jiangsu Wanbang Biopharmaceuticals Recent Developments
  139. 7.24 KPC Pharmaceuticals
  140. 7.24.1 KPC Pharmaceuticals Company Information
  141. 7.24.2 KPC Pharmaceuticals Business Overview
  142. 7.24.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  144. 7.24.5 KPC Pharmaceuticals Recent Developments
  145. 7.25 Mylan
  146. 7.25.1 Mylan Company Information
  147. 7.25.2 Mylan Business Overview
  148. 7.25.3 Mylan Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Mylan Antihyperuricemic Agents Product Portfolio
  150. 7.25.5 Mylan Recent Developments
  151. 7.26 Sun Pharmaceutical
  152. 7.26.1 Sun Pharmaceutical Company Information
  153. 7.26.2 Sun Pharmaceutical Business Overview
  154. 7.26.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio
  156. 7.26.5 Sun Pharmaceutical Recent Developments
  157. 7.27 Teva
  158. 7.27.1 Teva Company Information
  159. 7.27.2 Teva Business Overview
  160. 7.27.3 Teva Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Teva Antihyperuricemic Agents Product Portfolio
  162. 7.27.5 Teva Recent Developments
  163. 7.28 Tonghua Limin
  164. 7.28.1 Tonghua Limin Company Information
  165. 7.28.2 Tonghua Limin Business Overview
  166. 7.28.3 Tonghua Limin Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  167. 7.28.4 Tonghua Limin Antihyperuricemic Agents Product Portfolio
  168. 7.28.5 Tonghua Limin Recent Developments
  169. 7.29 Takeda Pharmaceuticals
  170. 7.29.1 Takeda Pharmaceuticals Company Information
  171. 7.29.2 Takeda Pharmaceuticals Business Overview
  172. 7.29.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  173. 7.29.4 Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  174. 7.29.5 Takeda Pharmaceuticals Recent Developments
  175. 7.30 YiChang HEC ChangJiang Pharmaceutical
  176. 7.30.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  177. 7.30.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  178. 7.30.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  179. 7.30.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio
  180. 7.30.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Antihyperuricemic Agents Market Size by Type
  2. 8.1.1 North America Antihyperuricemic Agents Revenue by Type (2021-2032)
  3. 8.1.2 North America Antihyperuricemic Agents Sales by Type (2021-2032)
  4. 8.1.3 North America Antihyperuricemic Agents Price by Type (2021-2032)
  5. 8.2 North America Antihyperuricemic Agents Market Size by Application
  6. 8.2.1 North America Antihyperuricemic Agents Revenue by Application (2021-2032)
  7. 8.2.2 North America Antihyperuricemic Agents Sales by Application (2021-2032)
  8. 8.2.3 North America Antihyperuricemic Agents Price by Application (2021-2032)
  9. 8.3 North America Antihyperuricemic Agents Market Size by Country
  10. 8.3.1 North America Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antihyperuricemic Agents Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Antihyperuricemic Agents Market Size by Type
  2. 9.1.1 Europe Antihyperuricemic Agents Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antihyperuricemic Agents Sales by Type (2021-2032)
  4. 9.1.3 Europe Antihyperuricemic Agents Price by Type (2021-2032)
  5. 9.2 Europe Antihyperuricemic Agents Market Size by Application
  6. 9.2.1 Europe Antihyperuricemic Agents Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antihyperuricemic Agents Sales by Application (2021-2032)
  8. 9.2.3 Europe Antihyperuricemic Agents Price by Application (2021-2032)
  9. 9.3 Europe Antihyperuricemic Agents Market Size by Country
  10. 9.3.1 Europe Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antihyperuricemic Agents Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Antihyperuricemic Agents Market Size by Type
  2. 10.1.1 China Antihyperuricemic Agents Revenue by Type (2021-2032)
  3. 10.1.2 China Antihyperuricemic Agents Sales by Type (2021-2032)
  4. 10.1.3 China Antihyperuricemic Agents Price by Type (2021-2032)
  5. 10.2 China Antihyperuricemic Agents Market Size by Application
  6. 10.2.1 China Antihyperuricemic Agents Revenue by Application (2021-2032)
  7. 10.2.2 China Antihyperuricemic Agents Sales by Application (2021-2032)
  8. 10.2.3 China Antihyperuricemic Agents Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antihyperuricemic Agents Market Size by Type
  2. 11.1.1 Asia Antihyperuricemic Agents Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antihyperuricemic Agents Sales by Type (2021-2032)
  4. 11.1.3 Asia Antihyperuricemic Agents Price by Type (2021-2032)
  5. 11.2 Asia Antihyperuricemic Agents Market Size by Application
  6. 11.2.1 Asia Antihyperuricemic Agents Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antihyperuricemic Agents Sales by Application (2021-2032)
  8. 11.2.3 Asia Antihyperuricemic Agents Price by Application (2021-2032)
  9. 11.3 Asia Antihyperuricemic Agents Market Size by Country
  10. 11.3.1 Asia Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antihyperuricemic Agents Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antihyperuricemic Agents Market Size by Type
  2. 12.1.1 SAMEA Antihyperuricemic Agents Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antihyperuricemic Agents Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antihyperuricemic Agents Price by Type (2021-2032)
  5. 12.2 SAMEA Antihyperuricemic Agents Market Size by Application
  6. 12.2.1 SAMEA Antihyperuricemic Agents Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antihyperuricemic Agents Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antihyperuricemic Agents Price by Application (2021-2032)
  9. 12.3 SAMEA Antihyperuricemic Agents Market Size by Country
  10. 12.3.1 SAMEA Antihyperuricemic Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antihyperuricemic Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antihyperuricemic Agents Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antihyperuricemic Agents Value Chain Analysis
  2. 13.1.1 Antihyperuricemic Agents Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antihyperuricemic Agents Production Mode & Process
  6. 13.2 Antihyperuricemic Agents Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antihyperuricemic Agents Distributors
  9. 13.2.3 Antihyperuricemic Agents Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst